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The intention of screening is to detect cancer early
enough so that it reduces mortality. It was only when
this intentionwas proven in randomised trials, and the
process considered worthwhile that national screening
programmes were introduced. Therefore, the informa-
tion traditionally provided by well-intentioned govern-
ment screening programmes was naturally biased in
favour of screening. This would have been considered
necessary for ensuring that asmanywomen as possible
got the beneﬁt of having their cancer detected early so
that they had the highest chance of cure.
The results of new analysis of the old randomised
trials, as well as widespread recognition of the over-
diagnosis that results from screening, suggest that the
balance between beneﬁt and harm from screeningmay
not be so clear cut. An extreme example of over-
diagnosis by screening is for neuroblastoma in in-
fancy; when this was initiated, a high incidence of such
tumours were found – a large proportion of these
never progressed and many regressed, which led to a
moratorium on screening for neuroblastoma. How-
ever, it is not as extreme for breast cancer. Arguably,
there can be four possible situations: (1) Screening is
clearly beneﬁcial – in that case there is a benevolent
reason to promote it. (2) Screening is clearly harmful –
in that case there is a benevolent reason to stop the
screening programme. (3) There is uncertainty about
the beneﬁt or harm – a position of equipoise – in this
case, one should only oﬀer screening within a ran-
domised trial. (4) The beneﬁt and harm are not clearly
quantiﬁable and are subject to individual value judge-
ments, which is probably the reality. In this case, one
needs to express the beneﬁts and harms in the most
comprehensible manner so that an individual woman
can make those value judgements and decide about
going for screening, whether fully, partly or not at all.
However, there are a few other issues that need to be
considered before a policy to stop the screening
programme is considered, because this could have
signiﬁcant unintended consequences.
With modern treatments, would the beneﬁt of
screening be ampliﬁed or diminished? Better surgery,
radiotherapy and adjuvant systemic therapy have sig-
niﬁcantly improved outcomes and there is an argument
that the window of opportunity oﬀered by mammo-
graphic screening is not relevant, because treatments
have become so much better. However, many current
treatments are only reﬁnements of older treatments,
and this might be a circular argument.
Even though the proportional beneﬁt of most
treatments is constant whatever the disease burden,
there could be a threshold below which the treatments
may be more eﬀective. Also, the good results of these
treatments are being seen at a time when screening has
become more widespread in recent years, and that
begs the question whether the two are synergistic.
Excellent modelling studies suggest that the beneﬁt
of treatment may be ampliﬁed by the presence of
screening (Figure 1).1 Will all this beneﬁt be reversed
if we stop screening and only treat symptomatic cases?
If there is any likelihood of this happening, then
measures to stop screening could have dangerous
unintended consequences. Therefore, any such changes
in policy must be ﬁrst tested in a randomised trial.
Does screening reduce the incidence of sympto-
matic cancer? It does not appear to reduce the absolute
number of symptomatic cases (Figure 2 elegantly
demonstrates overdiagnosis of invasive breast can-
cers). There will of course be some cancers that are
picked up early enough so that treatment is life-saving.
The price of overdiagnosis might, today, be at least
partially compensated for by less-aggressive treat-
ments that have been proven in randomised trials.
Most women who are diagnosed by screening have a
lumpectomy rather than mastectomy; they might be
treated with single dose-targeted intraoperative radio-
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Figure 1 Eﬀect of breast screening and adjuvant therapy on mortality from breast cancer. The estimated
combined eﬀect of screening and adjuvant therapy (black line in panel B) appears similar to the actual fall in
US breast cancer mortality (black line in panel A)
Estimated and Actual Rates of Death from Breast Cancer among Women 30 to 79 Years of Age from 1975 to 2000 (Panel A); Hypothetical
Assumptions about theUse of ScreeningMammography andAdjuvant Treatment (Panel B). Panel A, which compares themodel-based results
with the actual rates in theUnited States from1975 to 2000, shows the variability across themodel estimates. Someof themodelswere calibrated
according to the observed rate of death frombreast cancer in theUnited States, and somewere not. Panel B shows the results frommodelW (the
University of Wisconsin-Madison) of estimated mortality trends for the four scenarios considered: no screening and no adjuvant treatment;
base-case screening, but no adjuvant treatment; no screening, but base-case adjuvant treatment; base-case screening and adjuvant treatment.
Rates in both panels are age-adjusted to the 2000 US standard.
Figure 2 Eﬀect of screening mammography on the incidence of invasive cancer
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therapy (TARGIT),2–4withwhich there are fewer non-
breast cancer deaths compared with conventional
radiotherapy, as suggested by the Marmot commit-
tee;2 theymight also have a sentinel node biopsy rather
than an axillary clearance. So at least the majority of
overdiagnosed cases could have their full surgical and
radiotherapy treatment completed within a day-case
procedure, reducing the impact of overdiagnosis and
the harms that may have occurred by over-treatment.
Also, fewer women among these may have systemic
chemotherapy. It is conceivable that in those that do
require chemotherapy, there will be a few that fall into
the overdiagnosed category.
However, there is another point that is probably the
most important. The existence of a breast screening
programme brings with it the infrastructure and
quality assurance mechanisms that improve the treat-
ment of all breast cancers and therefore beneﬁts all
women – thosewith symptomatic and screen-detected
cancers. This substantial eﬀect cannot be under-
estimated. Can that be sustained without actually
screening? I doubt it. How do we continue giving
high-quality treatment to breast cancer patients with-
out having an infrastructure that supports it? Thus,
one of the arguments of stopping screening – reducing
opportunity costs – may not work at all, as the
resources might be diverted away from breast cancer,
and timely treatment of symptomatic breast cancer
that is an exemplar for other cancers, might really
suﬀer. Such actions may be more likely in today’s
times of austerity. One should remember that, unlike
manufacturing, provision of health always incurs a net
ﬁnancial loss to the provider: the proﬁt is health,
which may or may not translate into wealth, or if it
does, it only adds to the world pot of human endeav-
ours – not speciﬁcally to the hospital in which they
were treated.
Personally, I have a strong prejudice for giving all
information about screening to women in a compre-
hensible manner and have been an active promoter of
better information leaﬂets. However, I should remem-
ber that this is a prejudice. If we are adherers to
evidence, then we should recognise that there is no
evidence to suggest that changing information leaﬂets
such that they are equally balanced between ‘accept’ or
‘refuse’ invitation to screening rather than leaning
slightly towards screening, is beneﬁcial to a woman’s
well-being, or the well-being of the population.
At this point, we also need to consider which
outcome we are interested in and what is more
important – the sum total of happiness/well-being
of womankind, or personal length and quality of life
of each/most women, or ensuring that the personal
autonomy of every woman is preserved? But that is a
philosophical question that would need to be discussed
in another paper. In any case, if the information is
completely balanced then the only ethical action is to
do a randomised trial, as one cannot either oﬀer or
not-oﬀer screening with such an information leaﬂet.
However, if one has accepted the principle of oﬀering
screening, then by deﬁnition, the information leaﬂet
would be worded so as to justify screening even
though it is not ‘balanced’. One has to be internally
consistent and, of course there should be no hiding of
facts.
The only way we can legitimately challenge ‘a
screening programme which includes coercive infor-
mation leaﬂets to promote screening’ is to perform a
randomised trial, involving cluster randomisation of
regions within a larger community that currently does
not currently oﬀer a population screening programme,
and assess whether the introduction of a screening
programme reducesmortality in a trial design that can
diﬀerentiate between the beneﬁt from early detection
and beneﬁt from infrastructure for delivering high
quality care and whether there is any cost-saving, or
anxiety reduction.
Such a trial would includemodern and less aggress-
ive and equally eﬀective local treatments (such as
intraoperative radiotherapy or sentinel node biopsy
to reduce the impact of treatment of cancer) as well as
more eﬀective and optimised (e.g. targeted) systemic
therapies. Then we will have modern evidence to back
either of the prejudices.Wewould also gain important
insights into the natural history of breast cancer if the
trial design includes imaging studies that are kept
unread in those groups randomised to no screening,
if that is ethically allowable.
If one has to practice evidence-based policy, then
such a trial is essential before making any change in a
policy about promoting screening if we are to avoid
the unintended consequences of stopping screening.
The insight that screening is not a panacea is now
public knowledge.New treatments have become avail-
able that are less toxic and/or more eﬀective. Now is
the fertile time to do such a randomised trial (rather
than either introducing screening or making a deci-
sion to not introduce screening) in a community that
does not currently oﬀer screening – and this presents
an ethical, moral and ﬁnancial imperative.
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